In this study, the efficacy of the highly potent and selective MET tyrosine kinase inhibitor, ABN401, was investigated using histopathologic and genetic analyses (e.g., immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), and quantitative real-time PCR (q-PCR)) in MET-addicted cancer cell lines and patient-derived xenograft (PDX) models. The gene discussed is MET; the disease is cancer.